glp-1 agonists medications Examples: Which One Wins? New GLP-1 Guidelines for Type
Description
Retrieved from Rodriguez, P., Pantalone, K
A., Kind J., Kthe L
References (AMA 11th Edition) American Diabetes Association
Study findings The study cohort consisted of 36,082 and 234,028 GLP-1 receptor agonist and DPP-4 inhibitor users, respectively, who were followed for a median of 1.3 and 1.7 years
In some cases, the request may be denied, in which case the healthcare provider can appeal the decision, which may add additional time to the process
